mRNA and LNP CDMOs in Europe: 22 compared (2026)
22 of the 255 contract development and manufacturing organisations in A4BEE’s European census list mRNA and LNP manufacturing among their capabilities. The largest, with revenue over €1bn, are AGC Biologics and Patheon Italia. 8 sit between €250m and €1bn and 12 are smaller or niche.
By ownership: 4 family-owned, 6 private equity, 3 listed and 9 part of a pharma or industrial group. They are spread across 11 countries, led by Belgium (5), Germany (5), Poland (2), Sweden (2) and the United Kingdom (2). 8 of the 22 rows rest on audited reports or official company disclosures; the rest come from secondary sources or estimates.
22 companies
mRNA and LNP CDMOs in Europe
| Company | Country | Ownership | Size | Revenue (as reported) | Modalities | Data |
|---|---|---|---|---|---|---|
| AGC BiologicsCopenhagen site expanded to 16,000 L single-use; broad multi-modality platform. | Copenhagen, Denmark | Part of a pharma or industrial groupAGC Inc. | Tier 1 | ~US$1.2 bn (global) | Monoclonal antibody, Microbial and protein, mRNA and LNP, Viral vector and vaccine, Cell and gene therapy | medium |
| Patheon ItaliaItaly CDMO sites of Thermo Fisher (Patheon). Sterile/lyo + high-potency + mRNA/LNP. | Ferentino, Italy | Part of a pharma or industrial groupThermo Fisher Scientific | Tier 1 | not disclosed | Sterile fill-finish, Biologics and biosimilars, mRNA and LNP, Small-molecule API | low |
| BioSpringPrivately held German nucleic-acid CDMO (oligonucleotides — ASO, siRNA, guide RNA — plus mRNA). Fills a modality gap the roster otherwise lacks. | Frankfurt am Main, Germany | Family-owned | Tier 2 | not disclosed | mRNA and LNP, Small-molecule API | medium |
| CordenPharmaPeptide + lipid/LNP specialist riding the GLP-1 boom (e.g. Viking deal). | Basel, Switzerland | Private equity | Tier 2 | ~US$530 m | Peptide, mRNA and LNP, Sterile fill-finish, Small-molecule API | medium |
| ExotheraViral-vector and nucleic-acid CDMO; Univercells subsidiary. First CDMO with access to Quantoom's continuous-RNA Nfinity platform. | Jumet, Belgium | Part of a pharma or industrial groupUnivercells | Tier 2 | not disclosed | Viral vector and vaccine, mRNA and LNP, Cell and gene therapy | high |
| IDT BiologikaViral vaccine/vector + oncolytic virus specialist with mRNA fill-finish. | Dessau-Roßlau, Germany | Part of a pharma or industrial groupSK bioscience | Tier 2 | n/d | Viral vector and vaccine, Sterile fill-finish, mRNA and LNP | medium |
| Merck KGaA CDMOLife-Science CDMO arm covering biologics, ADC/HPAPI, viral vectors and LNP (via Exelead). | Darmstadt, Germany | ListedE. Merck KG | Tier 2 | not disclosed | Monoclonal antibody, Biologics and biosimilars, Antibody-drug conjugate (ADC), Viral vector and vaccine, mRNA and LNP | medium |
| NorthX BiologicsBiologics CDMO built on the former Cobra Biologics Matfors site; Swedish national innovation hub for ATMPs. | Matfors, Sweden | Private equityFlerie Invest | Tier 2 | not disclosed | Microbial and protein, Biologics and biosimilars, mRNA and LNP, Viral vector and vaccine, Cell and gene therapy, Monoclonal antibody, Sterile fill-finish | low |
| Quantoom BiosciencesmRNA manufacturing-platform and CDMO-enabling company (DNA/RNA production, formulation, reagents); Univercells group. | Nivelles, Belgium | Part of a pharma or industrial groupUnivercells | Tier 2 | not disclosed | mRNA and LNP | low |
| Recipharm | Stockholm, Sweden | Private equityEQT | Tier 2 | €827 m (2024) | Sterile fill-finish, Oral solid dose, Biologics and biosimilars, mRNA and LNP, Viral vector and vaccine | high |
| APC / VLE TherapeuticsIrish-founded (UCD spinout). APC = process-dev/CMC; sister VLE runs the GMP 'factory of the future' — the group has genuine manufacturing. | Dublin, Ireland | Family-owned | Tier 3 | not disclosed | Small-molecule API, Biologics and biosimilars, Viral vector and vaccine, mRNA and LNP | high |
| ArdenaNanomedicine/LNP + drug-substance/product + bioanalytical CDMO. | Ghent, Belgium | Private equityGHO Capital | Tier 3 | n/d | mRNA and LNP, Oral solid dose, Sterile fill-finish | medium |
| AxolabsOligonucleotide and nucleic-acid CRO/CDMO, part of LGC. Berlin cGMP oligo manufacturing. | Kulmbach, Germany | Part of a pharma or industrial groupLGC | Tier 3 | not disclosed | Small-molecule API, mRNA and LNP | medium |
| Celon Pharma | Łomianki, Poland | Listed | Tier 3 | PLN 207 m (2024) | Small-molecule API, mRNA and LNP, Biologics and biosimilars | high |
| eTheRNA immunotherapiesVenture-backed RNA/mRNA-LNP firm offering contract dev/manufacturing; positions as tech partner. Financial restructuring reported. | Niel, Belgium | Private equity | Tier 3 | not disclosed | mRNA and LNP | low |
| GenIbet BiopharmaceuticalsBiologics CDMO: microbial, cell culture, viral process dev + cGMP manufacture plus fill-finish. Made mRNA material for Moderna. | Oeiras, Portugal | Part of a pharma or industrial groupRecipharm | Tier 3 | not disclosed | Biologics and biosimilars, Microbial and protein, Viral vector and vaccine, Cell and gene therapy, mRNA and LNP, Sterile fill-finish | high |
| Kaneka EurogentecBiologics CDMO: microbial proteins, GMP plasmid DNA, oligonucleotides, peptides; added GMP mRNA (made a COVID vaccine). | Seraing, Belgium | Part of a pharma or industrial groupKaneka | Tier 3 | not disclosed | Biologics and biosimilars, Microbial and protein, mRNA and LNP, Peptide | high |
| Oxford BiomedicaLSE-listed pure-play viral-vector / cell & gene therapy CDMO (lentiviral, AAV, adenoviral). | Oxford, United Kingdom | Listed | Tier 3 | £128.8 m (FY2024) | Viral vector and vaccine, Cell and gene therapy, Biologics and biosimilars, mRNA and LNP | high |
| Polymun ScientificFamily-owned biopharma/liposome-LNP CDMO; scaled the LNP process for the BioNTech/Pfizer Comirnaty vaccine. | Klosterneuburg, Austria | Family-owned | Tier 3 | not disclosed | Biologics and biosimilars, mRNA and LNP, Viral vector and vaccine | high |
| SyVento BioTechGreenfield mRNA/LNP CDMO; MIA obtained 31 July 2025. | Skawina, Poland | Family-owned | Tier 3 | early-stage | mRNA and LNP | low |
| TouchlightCDMO making enzymatic 'doggybone DNA' (dbDNA) as template for mRNA/viral-vector/genetic medicines. First synthetic-DNA maker with MHRA GMP API cert. | London, United Kingdom | Private equity | Tier 3 | not disclosed | Cell and gene therapy, mRNA and LNP, Viral vector and vaccine | medium |
| Wacker BiotechHalle mRNA competence centre; microbial proteins + pDNA up to 1,500 L fermentation. | Munich, Germany | Part of a pharma or industrial groupWacker Chemie | Tier 3 | n/d | Microbial and protein, mRNA and LNP, Viral vector and vaccine | low |
Size: Tier 1 (revenue over €1bn) · Tier 2 (€250m–€1bn) · Tier 3 (under €250m or niche).
Revenue, staff and site figures are as reported and mix audited accounts with commercial estimates, which are often wrong for private companies. Each row carries a confidence mark; verify a figure before quoting it.
Browse the census
Other European CDMO lists
By country
- CDMOs in Italy (31)
- CDMOs in Spain (30)
- CDMOs in Germany (28)
- CDMOs in the United Kingdom (25)
- CDMOs in France (15)
- CDMOs in Switzerland (14)
- CDMOs in Poland (11)
- CDMOs in Belgium (9)
- CDMOs in Sweden (9)
- CDMOs in Greece (8)
- CDMOs in Ireland (8)
- CDMOs in the Netherlands (8)
- CDMOs in Portugal (8)
- CDMOs in Denmark (7)
- CDMOs in Austria (5)
- CDMOs in Finland (5)
- CDMOs in Norway (5)
- CDMOs in Czechia (4)
- CDMOs in Lithuania (4)
- CDMOs in Bulgaria (3)
By modality
- Small-molecule API CDMOs in Europe (107)
- Oral solid dose CDMOs in Europe (94)
- Sterile fill-finish CDMOs in Europe (106)
- Biologics and biosimilars CDMOs in Europe (66)
- Monoclonal antibody CDMOs in Europe (36)
- Antibody-drug conjugate (ADC) CDMOs in Europe (15)
- Cell and gene therapy CDMOs in Europe (29)
- mRNA and LNP CDMOs in Europe
- Viral vector and vaccine CDMOs in Europe (32)
- Microbial and protein CDMOs in Europe (34)
- Peptide CDMOs in Europe (24)